Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Acasti Pharma Inc. V.ACST

Alternate Symbol(s):  ACST

Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all which could help to increase treatment compliance and improve patient outcomes.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

GTX-104 positive results

As annouced today:  Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints :: Acasti Pharma Inc. (ACST) They have 3 products...read more

Acasti Pharma to Present

LAVAL, Qubec, April 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Prashant Kohli, Vice President of Commercial...read more

acasti

Credability at work.This stock has not yet met any significant forcast.Carepre was badly promoted and the real reason it failed has never been fully ex[plained.Later the promise of licensing Care pre...read more

RE:Over 200K on the bid, which is 1% of outstanding shares

Now 131,900 at the bid of $1.86 ... I think this or these buyers are very hungry buyers ... Let the wolves feast and pick up all the low hanging fruit awaiting conference news... hopefully very very...read more

RE:Oppenheimer report on Acasti, outperform, target US $6

ok, the issuance of the report triggered a rush to a high of $2.30 on Dec 22, 2021. I guess that the whole world knows of the report ... except that it takes time for analysis and thoughts and yes, I...read more

Oppenheimer report on Acasti, outperform, target US $6

Report dated Dec 21, 2021 ... Hum, graph looks great for any potential investor ...  rate and reply

Over 200K on the bid, which is 1% of outstanding shares

being whittled away at $1.85. Really good sign for the future!  rate and reply

SP Value

SP value is below cash in bank account. I didn't knew that this could be possible for a plublic company. Good job Jan!   rate and reply

RE:For the record

What a SH_IT Show this has been, thank god I dumped all my shares and moved on before they announced the final results, my spider sense told me  something was majorly wrong when they delayed the...read more

RE:Awarded Composition-of-Matter Patents for GTX-101

The best news here is the parents are good until 2036, which gives Jan plenty of time to f#$k this up again.... glta  rate and reply

Awarded Composition-of-Matter Patents for GTX-101

LAVAL, Qubec, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces that the European Patent Office, Chinese Patent Office...read more

Acasti pharma

This is directed to Francine ,a dedicated ACST follower and righty so based on data available. Francine, if you still own ACST stock I recomend you move some of your investment  into WML. You...read more

For the record

If you had invested $10,000 on Feb 7 2012, you would now have 245.87.  If you need any more evidence about this outfit, you should not be investing in stocks.  rate and reply

Nice to see the reverse split went well

Not we can lose more money on this lower board of directors. Why not just admit you suck and go get a real job and stop taking peoples money to dump. Clearly they don't have a clue what they'...read more

RE:RE:RE:Successful Completion of its Merger with Grace Therapeutics

No volume and no interest while insiders reward themselves for a job poorly done.  Who bought into the Jan D'Alvise BS?  How long will she have a job?  Too long!  rate and reply

RE:RE:Successful Completion of its Merger with Grace Therapeutics

Games, games and more games, so glad I dumped this one and moved on.....  rate and reply

RE:RE:RE:RE:RE:RE:Successful Completion of its Merger with Grace Therapeutics

Hi Weeble, its called a technical trade because 17% haircut for a pure reverse split annoncent a month ago was too much.  Even if Jan is the worst CEO in north america, I presume that she will...read more

RE:RE:RE:RE:RE:Successful Completion of its Merger with Grace Therapeutics

Francine, are you a masochist?  Good luck to you but I would never invest in a company where I didn't trust or like the CEO.  rate and reply

RE:RE:RE:RE:Successful Completion of its Merger with Grace Therapeutics

I sold my position during the 1.20US/1.50Cdn rally. Now buying at the equivalent of 34 cents is very compelling. I bought a small position this morning and will average down.  For Janelle, we...read more

RE:RE:RE:Successful Completion of its Merger with Grace Therapeutics

...exactly and part of deal is the inability to remove her...  rate and reply
The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >